Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis
- Autori: Patti F; Lo Fermo S; Vecchio R; Maimone D; Messina S; Gasperini C; Orefice V; Morra VB; Florio C; Amato MP; Goretti B; Portaccio E; Zipoli V; Bertolotto A; Bramanti P; Sessa E; Centonze D; Cottone S; Salemi G; Falcini M; Gallo P; Perini P; Gigli GL; Giuliani G; Grimaldi LM; Murri L; Lugaresi A; Monaco F; Montanari E; Motti L; Neri S; Paciello M; Provinciali L; Ragno M; Rosati G; Ruggieri S; Tola MR; Caniatti L; Tonali P; Batocchi AP; Trojano M; Di Monte E; De Caro MF; Ghezzi A; Zaffaroni M; Zolo P; Zorzon M; Signorino M; Scarpini E; Durelli L; Carolei A; Todaro M; Spitaleri D; Tartaglione A
- Anno di pubblicazione: 2010
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: cognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
- OA Link: http://hdl.handle.net/10447/46657
Abstract
The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNbeta-1a) on cognition in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Patients aged 18-50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score